Dongfeng-Fengshen H30 Cross Listed & Priced in China

Published on April 28, 2011 by Tycho de Feijter

The Dongfeng-Fengshen H30 Cross has been listed on the Chinese auto market. Price starts at 86.800 yuan and ends at 97.800 yuan. Engine a 1.6 mated to a 5-speed manual or 5-speed automatic. Fengshen is a sub brand for passenger cars from Dongfeng Automotive, they sell two other cars: the S30 sedan and the H30 hatchback where the H30 Cross is based on.


Beijing Auto Show Live: Dongfeng-Fengshen H30 Cross

Published on April 29, 2010 by Tycho de Feijter

Fengshen is a new subbrand for passenger cars from Dongfeng Automotive, they sell two cars so far: the S30 sedan and the H30 hatchback. Sales are not going too well, mostly because of the rather boring design of both vehicles. So Dongfeng came up with this H30 Cross with a new front, blacked wheel-arches and roofrails. Engine is a 1.6 litre with 78kw and 142nm. Price starts around 80.000 rmb. Chinese people love this kind of vehicles, the cross-versions of other brands are usually the top sellers of the range, so likely sales will indeed go up.


Dongfeng-Fengsheng H30 Cross NAKED

Published on April 16, 2010 by Tycho de Feijter

I do love those chrome mirrors. This is the brandnew Dongfeng-Fengsheng H30 Cross, Fengsheng being a brand of Dongfeng Automotive. Fengsheng is still small and makes boring cars like the standard H30 that doesn’t sell well. The very cool cross has to change that. It will cost around 85.000 rmb and come with a 1.6 litre with 78kw@5750rpm and 42nm@4000rpm. Debut at the Beijing Auto Show next week.


Spy Shots: Dongfeng H30 Cross

Published on March 30, 2010 by Tycho de Feijter

The Dongfeng-Fengshen H30, usually simply called ‘Dongfeng H30′, is a rather boring looking machine from Dongfeng Automotive. Dongfeng has joint ventures with Honda, Nissan, Peugeot (PSA) and Kia. The Fengshen-brand is Dongfeng’s first all-by-itself adventure on the passenger car market. To make a boring car a little bit more exciting Dongfeng decided to go for the Cross-treatment.

Read more »